U.S. September retail sales data was better than expected, plus the regional manufacturing activities began to warm up, pushing the U.S stock market to open higher and move up, with the three major stocks indexes closing green. The medical sector led the gainers today.
Internet Gold Golden Lines Ltd. (IGLD) is a communications services provider through its subsidiary, B Communications Ltd., controls Bezeq, which is the principal provider of communications services in Israel. IGLD stock price popped up 27.28%, or $0.82, to $3.84, marking the biggest winner among the top stocks today. There were not catalysts supporting this move of IGLD shares. IGLD stock traded 80,420 shares, heavier than the average trading volume of 11,14 shares. The company has a market cap of $73.74 million. Stock price of B Communications Ltd (BCOM) also jumped 26.46%, or $1.27, to $6.07 on Monday. The intraday volume was 147,7401 shares, well above the average daily trading volume of 12,587 shares. B Communications has a market cap of $181.43 million.
After the big gains of coal stocks last week, James River Coal Company (JRCC) continued to climb 23.20%, or $0.90, to $4.78, with 6.21 million shares traded, much more than the average daily trading volume of 1.45 million shares. James River Coal Company is primarily engaged in processing and selling of thermal and metallurgical coal and has a market cap of $171.55 million.
Cyclacel Pharmaceuticals Inc (CYCC), among the top stocks on Monday, is a development-stage biopharmaceutical company focused on mechanism-targeted drugs to treat human cancers and other serious disorders in the United States and the United Kingdom. CYCC stock price surged 22.49%, or $1.23, to $6.70 on a volume of 2.38 million shares, well above the average trading volume of 98,938 shares, after the company announced the results of Phase 2 randomized trial of oral sapacitabine capsules, which showed that expected survival of elderly patients with MDS nearly doubled. Cyclacel Pharmaceuticals currently has a market cap of $56.48 million.
Another medical company also came in as one of the top stocks today. Dyax Corp. (DYAX) is a biopharmaceutical company engaged in the treatments for conditions identified as plasma kallikrein (bradykinin) mediated angioedema. Dyax Corp and Kadmon Corporation signed a strategic licensing agreement last month, pursuant to which, the latter has been granted an exclusive worldwide license for the development and commercialization of the fully human monoclonal antibody DX-2400. Dyax will receive an upfront payment and is eligible for significant development and commercial milestone payments. DYAX stock price hiked 18.49%, or $0.44, to $2.82, on a volume of 695,369 shares, topping the average daily trading volume of 247,142 shares. Dyax has a market cap of $279,28 million.